Skip to main content

Market Overview

Canaccord: Buy The Dip In Nevro After Disappointing Quarterly Report

Canaccord: Buy The Dip In Nevro After Disappointing Quarterly Report

Medical device manufacturer Nevro Corp (NYSE: NVRO)'s shares are tumbling after the company's first-quarter report after the close Monday. 

Nevro reported a wider-than-expected loss of 51 cents per share and below-consensus revenue for the quarter, while it reiterated its full-year 2018 revenue guidance.

The Analyst

Canaccord Genuity analyst Jason Mills maintained a Buy rating on Nevro and lowered the price target from $110 to $102.

The Thesis

The disappointment relative to expectations was mainly due to higher-than-anticipated seasonality, Mills said in a Tuesday note.

Structurally, the company is on solid footing, the analyst said. Nevro continued to add healthy numbers to its domestic salesforce, he said. 

The sequential slowdown in growth and share loss were due to challenging comparisons, as Nevro reported a blowout fourth-quarter of 2017 — and Q1 saw competitor product launches from Boston Scientific Corporation (NYSE: BSX) and Medtronic PLC (NYSE: MDT), according to Canaccord. 

Nevro has grown in scale relative to competitors that are much larger and has been more impacted by seasonality as a result, Mills said. On a year-over-year basis, Nevro is clearly gaining market share, he said. 

Canaccord views the stock as being undervalued.

"In sum, while the quarter was clearly not the result we expected, we think the right move for investors, when they look back 12 months from now, will have been to accumulate shares on weakness," Mills said. 

Canaccord identified positive tailwinds in the spinal cord stimulation market, continued expansion of Nevro's sales force and the potential for an expansion in the company's total addressable market. 

The Price Action

Nevro shares were plunging nearly 16 percent to $77.62 at the time of publication Tuesday. 

Related Links:

Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Photo courtesy of Nevro Corp. 

Latest Ratings for NVRO

Feb 2021Morgan StanleyMaintainsOverweight
Feb 2021Piper SandlerInitiates Coverage OnOverweight
Jan 2021SVB LeerinkMaintainsOutperform

View More Analyst Ratings for NVRO
View the Latest Analyst Ratings


Related Articles (NVRO)

View Comments and Join the Discussion!

Posted-In: Analyst Color Earnings News Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga

Latest Ratings

SEAutonomous ResearchInitiates Coverage On378.0
ALHCMorgan StanleyInitiates Coverage On36.0
ALHCRaymond JamesInitiates Coverage On30.0
HAEMorgan StanleyDowngrades83.0
DISWells FargoMaintains219.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at